Semaglutide, Dulaglutide, and Tirzepatide Have Similar GI Side Effect Profiles
A large real-world comparison found no meaningful differences in severe gastrointestinal adverse events between dulaglutide, semaglutide, and tirzepatide in type 2 diabetes patients.
Quick Facts
What This Study Found
No significant differences in composite GI adverse events were found: semaglutide vs dulaglutide HR 0.96 (0.87-1.06), tirzepatide vs dulaglutide HR 0.96 (0.77-1.20), tirzepatide vs semaglutide HR 1.07 (0.90-1.26).
Key Numbers
How They Did This
New-user, active-comparator cohort study with 1:1 propensity score matching across three pairwise comparisons using population-based data from January 2019 to August 2024.
Why This Research Matters
Patients and clinicians often worry about GI side effects when choosing between GLP-1 drugs. This evidence showing equivalent safety profiles allows treatment decisions to be based on other factors like efficacy and cost.
The Bigger Picture
As the GLP-1 drug market expands with multiple options, head-to-head safety data helps clinicians and patients make informed choices. This study provides reassurance that switching between these peptide drugs doesn't meaningfully change GI risk.
What This Study Doesn't Tell Us
Possible residual confounding by glycemic control and BMI. Observational design. May not capture milder GI symptoms that don't result in medical encounters or diagnoses.
Questions This Raises
- ?Do dose-dependent differences in GI safety emerge at higher titration levels of each drug?
- ?How does GI safety compare when these drugs are used for obesity (higher doses) rather than diabetes?
- ?Are there subpopulations (e.g., those with prior GI conditions) where safety differences might emerge?
Trust & Context
- Key Stat:
- No significant difference All three GLP-1 drugs showed similar rates of serious GI events including pancreatitis, biliary disease, and bowel obstruction
- Evidence Grade:
- Large population-based cohort study with propensity-score matching and active comparators. Strong real-world evidence, though observational design limits causal inference.
- Study Age:
- Published in 2025 using data through August 2024, reflecting current prescribing patterns.
- Original Title:
- Comparative Gastrointestinal Safety of Dulaglutide, Semaglutide, and Tirzepatide in Adults With Type 2 Diabetes.
- Published In:
- Annals of internal medicine, 179(1), 1-11 (2026)
- Authors:
- Crisafulli, Salvatore, Alkabbani, Wajd(2), Paik, Julie M(5), Bykov, Katsiaryna, Tavakkoli, Ali, Glynn, Robert J, Htoo, Phyo T, Yu, Elaine W, Trifirò, Gianluca, Wexler, Deborah J, Patorno, Elisabetta
- Database ID:
- RPEP-15059
Evidence Hierarchy
Frequently Asked Questions
Which GLP-1 drug has the fewest stomach side effects?
This large study found no meaningful differences in serious GI side effects between dulaglutide, semaglutide, and tirzepatide. All three had similar rates of pancreatitis, biliary problems, bowel obstruction, gastroparesis, and severe constipation.
Should I worry about stomach problems when switching between GLP-1 medications?
This evidence suggests switching between dulaglutide, semaglutide, and tirzepatide does not meaningfully change your risk of serious GI complications. However, individual tolerance to milder symptoms like nausea may still vary.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15059APA
Crisafulli, Salvatore; Alkabbani, Wajd; Paik, Julie M; Bykov, Katsiaryna; Tavakkoli, Ali; Glynn, Robert J; Htoo, Phyo T; Yu, Elaine W; Trifirò, Gianluca; Wexler, Deborah J; Patorno, Elisabetta. (2026). Comparative Gastrointestinal Safety of Dulaglutide, Semaglutide, and Tirzepatide in Adults With Type 2 Diabetes.. Annals of internal medicine, 179(1), 1-11. https://doi.org/10.7326/ANNALS-25-01724
MLA
Crisafulli, Salvatore, et al. "Comparative Gastrointestinal Safety of Dulaglutide, Semaglutide, and Tirzepatide in Adults With Type 2 Diabetes.." Annals of internal medicine, 2026. https://doi.org/10.7326/ANNALS-25-01724
RethinkPeptides
RethinkPeptides Research Database. "Comparative Gastrointestinal Safety of Dulaglutide, Semaglut..." RPEP-15059. Retrieved from https://rethinkpeptides.com/research/crisafulli-2026-comparative-gastrointestinal-safety-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.